staa-8k_20220810.htm

0001564590-22-028940.txt : 20220810 0001564590-22-028940.hdr.sgml : 20220810 20220810161027 ACCESSION NUMBER: 0001564590-22-028940 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 14 CONFORMED PERIOD OF REPORT: 20220810 ITEM INFORMATION: Results of Operations and Financial Condition ITEM INFORMATION: Financial Statements and Exhibits FILED AS OF DATE: 20220810 DATE AS OF CHANGE: 20220810 FILER: COMPANY DATA: COMPANY CONFORMED NAME: STAAR SURGICAL CO CENTRAL INDEX KEY: 0000718937 STANDARD INDUSTRIAL CLASSIFICATION: OPHTHALMIC GOODS [3851] IRS NUMBER: 953797439 STATE OF INCORPORATION: DE FISCAL YEAR END: 1230 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 000-11634 FILM NUMBER: 221151923 BUSINESS ADDRESS: STREET 1: 1911 WALKER AVE CITY: MONROVIA STATE: CA ZIP: 91016 BUSINESS PHONE: 6263037902 MAIL ADDRESS: STREET 1: 1911 WALKER AVE CITY: MONROVIA STATE: CA ZIP: 91016 FORMER COMPANY: FORMER CONFORMED NAME: STAAR SURGICAL COMPANY DATE OF NAME CHANGE: 19920703 8-K 1 staa-8k_20220810.htm 8-K staa-8k_20220810.htm

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, DC 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

Date of report (Date of earliest event reported): August 10, 2022

STAAR Surgical Company

(Exact Name of Registrant as Specified in Charter)

Delaware	0-11634	95-3797439
(State or Other Jurisdiction of Incorporation)	(Commission File Number)	(IRS Employer Identification No.)

25651 Atlantic Ocean Drive Lake Forest, California		92630
(Address of Principal Executive Offices)		(Zip Code)

Registrant’s Telephone Number, Including Area Code: 626-303-7902

Not Applicable

(Former Name or Former Address, if Changed Since Last Report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

☐	Written communication pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
☐	Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
☐	Pre-commencement communication pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
☐	Pre-commencement communication pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:


Title of each class	Trading Symbol(s)	Name of each exchange on which registered
Common	STAA	NASDAQ

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1 933 (17 CFR §230.405) or Rule 12b-2 of the Securities Exchange Act of 1934 (17 CFR §240.12b-2).

Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Item 2.02 Results of Operations and Financial Condition.

On August 10, 2022, STAAR Surgical Company (the “Company”) published a press release reporting its financial results for the quarter ended July 1, 2022, a copy of which is furnished as Exhibit 99.1 to this report and is incorporated herein by this reference.

This information and the information contained in the press release shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, or otherwise subject to the liabilities of that section. The information in Item 2.02 of this Current Report, and Exhibit 99.1 are not incorporated by reference into any filings of STAAR made under the Securities Act of 1933, as amended, whether made before or after the date of this Current Report, regardless of any general incorporation language in the filing unless specifically stated so therein.

Item 9.01 Financial Statements and Exhibits


Exhibit No.		Description

99.1		Press release of the Company dated August 10, 2022.

104		Cover Page Interactive Data File (embedded within the Inline XBRL document).

SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.


STAAR Surgical Company

August 10, 2022	By:	/s/ Caren Mason
		Caren Mason
		President and Chief Executive Officer

EX-99.1 2 staa-ex991_6.htm EX-99.1 staa-ex991_6.htm

Exhibit 99.1

STAAR Surgical Reports Record Second Quarter Net Sales of $81.1 Million Up 30% Y/Y

ICL Units Up 42% Y/Y; Constant Currency Net Sales of $84.2 Million

Announces Partnership with Joe Jonas to Raise EVO Global Awareness

LAKE FOREST, CA, August 10, 2022 --- STAAR Surgical Company (NASDAQ: STAA), a leading developer, manufacturer and marketer of implantable lenses and companion delivery systems for the eye, today reported financial results for the second quarter ended July 1, 2022.

Second Quarter 2022 Overview

•

Record Net Sales of $81.1 Million Up 30% and Constant Currency Net Sales of $84.2 Million Up 35% from the Prior Year Quarter

•

Record ICL Sales of $77.9 Million Up 32% and Constant Currency ICL Sales of $80.5 Million Up 36% from the Prior Year Quarter

•

Record ICL Units Up 42% from the Prior Year Quarter

•

Gross Margin at 78.8% vs. 78.9% in the Prior Year Quarter

•

Net Income of $0.26 per Share vs. $0.17 per Share in the Prior Year Quarter

•

Cash and Cash Equivalents Ended the Quarter at $202.5 Million

“We achieved 30% sales growth and a record level of sales in the second quarter while advancing our EVO ICL Family of Lenses including in China and the U.S., the two largest market opportunities for refractive vision correction. The entire STAAR organization is energized by our ability to effectively manage COVID-19 challenges during the quarter, exceed our growth commitments and vault to a new record level of $81.1 million in quarterly net sales despite foreign currency headwinds,” said Caren Mason, President and CEO of STAAR Surgical. “In the second quarter, we achieved strong global ICL unit growth up 42% highlighted by unit growth in China up 45%, the U.S. up 36%, Japan up 41%, India up 181% and Asia Pacific distributor markets up 66%, all as compared to the prior year quarter. We are very proud to achieve the second quarter milestone results while also holding fast to our culture of quality and manufacturing excellence which contributed to our official five-year MDR Certification on July 15, 2022.”

Ms. Mason continued, “The U.S. commercial launch of our EVO family of myopia lenses is well underway, and we are thrilled to announce our partnership today with Joe Jonas, who earlier this month received EVO lenses to correct his distance vision. In the next several weeks, Joe will begin sharing his journey to Visual Freedom via a global advertising, marketing and social media campaign. Our goal in the U.S. is to drive awareness and education of the benefits and Visual Freedom offered by our lenses. Joe Jonas needed EVO lenses below -5.0 diopters to correct his myopia and chose EVO. He is thrilled with the outcome which further demonstrates that EVO is an excellent solution for achieving Visual Freedom at all approved levels - low, mid and high, along the diopter curve. Next month we will showcase our entire EVO Family of Lenses at our Experts Meeting and the 40^th Annual Congress of the European Society of Cataract and Refractive Surgeons in Milan, Italy where we will feature Viva, an innovative lens for individuals with presbyopia. Finally, we are today reaffirming our previously provided outlook for fiscal 2022 net sales of approximately $295 million, which takes into account a significant currency headwind and a continuation of the current level of COVID-19 related challenges in China and elsewhere, offset by stronger than expected demand for our EVO lenses, which has continued through the beginning of the third quarter.”

Financial Overview – Q2 2022

Net sales were $81.1 million for the second quarter of 2022, up 30% compared to $62.4 million reported in the prior year quarter. The sales increase was driven by ICL sales and unit growth of 32% and 42%, respectively, as compared to the prior year period. Other Product sales increased 1% compared to the prior year quarter. ICL sales were 96% of total Net sales for the second quarter of 2022. Changes in currency, primarily in the Japanese Yen as well as the Euro, negatively impacted reported total net sales by $3.1 million for the second quarter of 2022.

Gross profit margin for the second quarter of 2022 was 78.8% compared to the prior year quarter of 78.9%. Factors impacting gross margin in the second quarter of 2022, as compared to the prior year quarter, include an inventory reserve recognized as a result of discontinuance of Visian ICL in the U.S. and increased period costs associated with manufacturing projects, offset by favorable product and geographic sales mix.

Operating expenses for the second quarter of 2022 were $46.9 million compared to the prior year quarter of $38.6 million. General and administrative expenses were $14.0 million compared to the prior year quarter of $11.4 million. The increase in general and administrative expenses was due to increased facilities costs and compensation related expenses. Selling and marketing expenses were $24.2 million compared to the prior year quarter of $18.9 million. The increase in selling and marketing expenses is due to increased marketing, promotion and advertising expenses and trade show expenses, partially offset by decreased compensation related expenses. Research and development expenses were $8.6 million compared to the prior year quarter of $8.3 million due to increased compensation related expenses, partially offset by lower clinical trial expenses.

Net income for the second quarter of 2022 was $13.0 million or $0.26 per diluted share compared with net income of $8.6 million or $0.17 per diluted share for the prior year quarter. The year over year increase is attributable to higher sales and gross profit and, as a percentage of sales, lower operating expenses. Adjusted Net Income for the second quarter of 2022 was $20.7 million or $0.42 per diluted share compared to $13.5 million or $0.27 per diluted share for the prior year quarter. The reconciliation between GAAP and non-GAAP financial information is provided in the financial tables included with this release.

Cash and cash equivalents at July 1, 2022 totaled $202.5 million compared to $199.7 million at December 31, 2021.

Conference Call

The Company will host a conference call and webcast today, Wednesday, August 10 at 4:30 p.m. Eastern / 1:30 p.m. Pacific to discuss its financial results and operational progress. To access the conference call (Access Code 904311), please dial 844-200-6205 for domestic participants and 929-526-1599 for international participants. The live webcast can be accessed from the investor relations section of the STAAR website at www.staar.com.

A taped replay of the conference call (Replay Code 944172) will be available beginning approximately one hour after the call’s conclusion for seven days. This replay can be accessed by dialing 866-813-9403 for domestic callers and 929-458-6194 for international callers. An archived webcast will also be available at www.staar.com.

Use of Non-GAAP Financial Measures

This press release includes supplemental non-GAAP financial information, which STAAR believes investors will find helpful in understanding its operating performance. “Adjusted Net Income” excludes the following items that are included in “Net Income” as calculated in accordance with U.S. generally accepted accounting principles (“GAAP”): gain or loss on foreign currency transactions, stock-based compensation expenses, and valuation allowance adjustments. Management believes that “Adjusted Net Income” is useful to investors in gauging the outcome of the key drivers of the business performance: the ability to increase sales revenue and our ability to increase profit margin by improving the mix of high value products while reducing the costs over which management has control.

Management has also excluded gains and losses on foreign currency transactions because of the significant fluctuations that can result from period to period as a result of market driven factors. Stock-based compensation expenses consist of expenses for stock options and restricted stock under the Financial Accounting Standards Board’s Accounting Standards Codification (ASC) 718. Valuation allowance adjustments can occur from time to time based on forecasted changes in operating results until all net operating loss carryforwards are fully utilized. In calculating Adjusted Net Income, STAAR excludes stock-based compensation expenses and valuation allowance adjustments because they are non-cash expenses and because of the considerable judgment involved in calculating their values. In addition, these expenses tend to be driven by fluctuations in the price of our stock and not by the same factors that generally affect our other business expenses.

The Company also uses Constant Currency as a Non-GAAP financial measure to exclude the effects of currency fluctuations on net sales. The Company conducts a significant part of its activities outside the U.S. It receives sales revenue and pays expenses principally in U.S. dollars, Swiss francs, Japanese yen and euros. The exchange rates between dollars and non-U.S. currencies can fluctuate greatly and can have a significant effect on the Company’s results when reported in U.S. dollars. In order to compare the Company's performance from period to period without the effect of currency, the Company will apply the same average exchange rate applicable in the prior period, or the

"constant currency" rate to sales or expenses in the current period as well. Because changes in currency are outside of the control of the Company and its managers, management finds this non-GAAP measure useful in determining the long-term progress of its initiatives and determining whether its managers are achieving their performance goals. The Company believes that the non-GAAP constant-currency sales results measures provided in this press release are similarly useful to investors to give insight on long term trends in the Company's performance without the external effect of changes in relative currency values. The table provided in this press release shows sales results calculated in accordance with GAAP, the effect of currency, and the resulting non-GAAP measure expressed in constant currency.

About STAAR Surgical

STAAR, which has been dedicated solely to ophthalmic surgery for over 40 years, designs, develops, manufactures and markets implantable lenses for the eye with companion delivery systems. These lenses are intended to provide visual freedom for patients, lessening or eliminating the reliance on glasses or contact lenses. All of these lenses are foldable, which permits the surgeon to insert them through a small incision. STAAR’s lens used in refractive surgery is called an Implantable Collamer® Lens or “ICL”, which includes the EVO Visian ICL™ product line. More than 2,000,000 Visian^® ICLs have been sold to date and STAAR markets these lenses in over 75 countries. To learn more about the ICL go to: EVOICL.com. Headquartered in Lake Forest, CA, the company operates manufacturing and packaging facilities in Aliso Viejo, CA, Monrovia, CA and Nidau, Switzerland. For more information, please visit the Company’s website at www.staar.com.

Safe Harbor

All statements that are not statements of historical fact are forward-looking statements, including statements about any of the following: any financial projections (including sales), plans, strategies, and objectives of management for 2022 or prospects for achieving such plans, expectations for sales, revenue, margin, expenses or earnings, the expected impact of the COVID-19 pandemic and related public health measures (including but not limited to its impact on sales, operations or clinical trials globally), product safety or effectiveness, the status of our current and pipeline of ICL products with regulators, and any statements of assumptions underlying any of the foregoing, including those relating to our current and pipeline of ICL products and market expansion activities. Important factors that could cause actual results to differ materially from those indicated by such forward-looking statements include risks and uncertainties related to the COVID-19 pandemic and related public health measures, as well as the factors set forth in the Company’s Annual Report on Form 10-K for the year ended December 31, 2021 under the caption “Risk Factors,” which is on file with the Securities and Exchange Commission and available in the “Investor Information” section of the company’s website under the heading “SEC Filings.” We disclaim any intention or obligation to update or revise any financial projections or forward-looking statement due to new information or events. These statements are based on expectations and assumptions as of the date of this press release and are subject to numerous risks and uncertainties, which could cause actual results to differ materially from those described in the forward-looking statements. The risks and uncertainties include the following: global economic conditions; the impact of the COVID-19 pandemic on markets; the discretion of regulatory agencies to approve or reject existing, new or improved products, or to require additional actions before approval, or to take enforcement action; international trade disputes; and the willingness of surgeons and patients to adopt a new or improved product and procedure.

CONTACT:

Investors

Brian Moore

Vice President, Investor, Media Relations and Corporate Development

(626) 303-7902, Ext. 3023

bmoore@staar.com

Media

Jen Jones

Gold PR | Social Media

(310) 918-4313

jjones@goldpr.com

Consolidated Balance Sheets

(in 000's)

Unaudited

	July 1, 2022			December 31, 2021
ASSETS
Current assets:
Cash and cash equivalents	$	202,490		$	199,706
Accounts receivable trade, net		62,811			43,531
Inventories, net		18,089			17,274
Prepayments, deposits, and other current assets		13,066			10,900
Total current assets		296,456			271,411
Property, plant, and equipment, net		42,813			35,912
Finance lease right-of-use assets, net		420			506
Operating lease right-of-use assets, net		30,363			31,310
Intangible assets, net		184			218
Goodwill		1,786			1,786
Deferred income taxes		3,217			3,813
Other assets		786			822
Total assets	$	376,025		$	345,778

LIABILITIES AND STOCKHOLDERS' EQUITY
Current liabilities:
Accounts payable	$	12,716		$	8,699
Obligations under finance leases		166			127
Obligations under operating leases		3,708			3,283
Allowance for sales returns		5,550			4,816
Other current liabilities		24,374			31,877
Total current liabilities		46,514			48,802
Obligations under finance leases		295			382
Obligations under operating leases		26,880			28,269
Deferred income taxes		1,037			811
Asset retirement obligations		169			198
Pension liability		1,823			8,758
Total liabilities		76,718			87,220
Stockholders' equity:
Common stock		480			477
Additional paid-in capital		387,328			373,519
Accumulated other comprehensive loss		249			(4,048	)
Accumulated deficit		(88,750	)		(111,390	)
Total stockholders' equity		299,307			258,558
Total liabilities and stockholders' equity	$	376,025		$	345,778

Consolidated Statements of Income

(In 000's except for per share data)

Unaudited

	Three Months Ended																		Six Months Ended
													Fav (Unfav)																		Fav (Unfav)
	% of Sales			July 1, 2021			% of Sales			July 2, 2021			Amount			%			% of Sales			July 1, 2022			% of Sales			July 2, 2021			Amount			%
Net sales		100.0	%	$	81,101			100.0	%	$	62,367		$	18,734			30.0	%		100.0	%	$	144,301			100.0	%	$	113,119		$	31,182			27.6	%
Cost of sales		21.2	%		17,229			21.1	%		13,164			(4,065	)		-30.9	%		21.6	%		31,165			21.9	%		24,774			(6,391	)		-25.8	%
Gross profit		78.8	%		63,872			78.9	%		49,203			14,669			29.8	%		78.4	%		113,136			78.1	%		88,345			24,791			28.1	%
Selling, general and administrative expenses:
General and administrative		17.2	%		13,983			18.4	%		11,441			(2,542	)		-22.2	%		18.0	%		25,923			19.1	%		21,653			(4,270	)		-19.7	%
Selling and marketing		29.9	%		24,233			30.2	%		18,853			(5,380	)		-28.5	%		28.8	%		41,503			28.4	%		32,054			(9,449	)		-29.5	%
Research and development		10.7	%		8,636			13.2	%		8,260			(376	)		-4.6	%		11.4	%		16,577			14.6	%		16,519			(58	)		-0.4	%
Total selling, general, and administrative expenses		57.8	%		46,852			61.8	%		38,554			(8,298	)		-21.5	%		58.2	%		84,003			62.1	%		70,226			(13,777	)		-19.6	%
Operating income		21.0	%		17,020			17.1	%		10,649			6,371			59.8	%		20.2	%		29,133			16.0	%		18,119			11,014			60.8	%
Other expense, net:
Interest income (expense), net		0.1	%		43			0.0	%		(5	)		48			960.0	%		0.0	%		37			0.0	%		(12	)		49			408.3	%
Loss on foreign currency transactions		-2.3	%		(1,860	)		-0.2	%		(131	)		(1,729	)		-1319.8	%		-1.9	%		(2,775	)		-1.3	%		(1,430	)		(1,345	)		-94.1	%
Royalty income		0.2	%		177			0.2	%		151			26			17.2	%		0.3	%		450			0.3	%		311			139			44.7	%
Other income (expense), net		0.1	%		89			0.1	%		51			38			74.5	%		0.1	%		151			0.0	%		(34	)		185			544.1	%
Total other income (expense), net		-1.9	%		(1,551	)		0.1	%		66			(1,617	)		-2450.0	%		-1.5	%		(2,137	)		-1.0	%		(1,165	)		(972	)		-83.4	%
Income before provision for income taxes		19.1	%		15,469			17.2	%		10,715			4,754			44.4	%		18.7	%		26,996			15.0	%		16,954			10,042			59.2	%
Provision for income taxes		3.0	%		2,431			3.5	%		2,148			(283	)		-13.2	%		3.0	%		4,356			3.0	%		3,395			(961	)		-28.3	%
Net income		16.1	%	$	13,038			13.7	%	$	8,567		$	4,471			52.2	%		15.7	%	$	22,640			12.0	%	$	13,559		$	9,081			67.0	%
Net income per share - basic				$	0.27					$	0.18											$	0.47					$	0.29
Net income per share - diluted				$	0.26					$	0.17											$	0.46					$	0.27
Weighted average shares outstanding - basic					47,889						47,099												47,822						46,858
Weighted average shares outstanding - diluted					49,223						49,491												49,264						49,373

Consolidated Statements of Cash Flows

(in 000's)

Unaudited

	Three Months Ended						Six Months Ended
	July 1, 2022			July 2, 2021			July 1, 2022			July 2, 2021
Cash flows from operating activities:
Net income	$	13,038		$	8,567		$	22,640		$	13,559
Adjustments to reconcile net income to net cash provided by operating activities:
Depreciation of property and equipment		1,030			889			2,024			1,754
Amortization of long-lived intangibles		7			8			15			17
Deferred income taxes		-			845			-			845
Change in net pension liability		11			(154	)		52			(27	)
Stock-based compensation expense		5,754			3,992			9,648			7,322
Loss on disposal of property and equipment		-			-			-			2
Provision for sales returns and bad debts		994			829			800			932
Inventory provision		994			313			1,428			697
Changes in working capital:
Accounts receivable		(16,210	)		(14,935	)		(20,137	)		(13,797	)
Inventories		(342	)		1,254			(1,825	)		2,238
Prepayments, deposits and other current assets		2,245			(164	)		(2,260	)		(307	)
Accounts payable		575			131			3,243			(268	)
Other current liabilities		5,150			4,807			(6,992	)		181
Net cash provided by operating activities		13,246			6,382			8,636			13,148
Cash flows from investing activities:
Acquisition of property and equipment		(5,271	)		(3,524	)		(7,810	)		(5,683	)
Net cash used in investing activities		(5,271	)		(3,524	)		(7,810	)		(5,683	)
Cash flows from financing activities:
Repayment of finance lease obligations		(27	)		(43	)		(45	)		(278	)
Proceeds from vested restricted stock and exercise of stock options		2,234			7,876			3,146			14,111
Net cash provided by financing activities		2,207			7,833			3,101			13,833
Effect of exchange rate changes on cash and cash equivalents		(759	)		48			(1,143	)		(668	)
Increase in cash and cash equivalents		9,423			10,739			2,784			20,630
Cash and cash equivalents, at beginning of the period		193,067			162,344			199,706			152,453
Cash and cash equivalents, at end of the period	$	202,490		$	173,083		$	202,490		$	173,083

Reconciliation of Non-GAAP Financial Measure

Adjusted Net Income and Net Income Per Share

(in 000's)

Unaudited

	Three Months Ended				Six Months Ended
	July 1, 2022		July 2, 2021		July 1, 2022		July 2, 2021
Net income (as reported)	$	13,038	$	8,567	$	22,640	$	13,559
Less:
Foreign currency impact		1,860		131		2,775		1,430
Stock-based compensation expense		5,754		3,992		9,648		7,322
Valuation allowance adjustment		-		845		-		845
Net income (adjusted)	$	20,652	$	13,535	$	35,063	$	23,156
Net income per share, basic (as reported)	$	0.27	$	0.18	$	0.47	$	0.29
Foreign currency impact		0.04		-		0.06		0.03
Stock-based compensation expense		0.12		0.09		0.20		0.15
Valuation allowance adjustment		-		0.02		-		0.02
Net income per share, basic (adjusted)	$	0.43	$	0.29	$	0.73	$	0.49
Net income per share, diluted (as reported)	$	0.26	$	0.17	$	0.46	$	0.27
Foreign currency impact		0.04		-		0.06		0.03
Stock-based compensation expense		0.12		0.08		0.19		0.15
Valuation allowance adjustment		-		0.02		-		0.02
Net income per share, diluted (adjusted)	$	0.42	$	0.27	$	0.71	$	0.47
Weighted average shares outstanding - Basic		47,889		47,099		47,822		46,858
Weighted average shares outstanding - Diluted		49,223		49,491		49,264		49,373

Note: Net income per share (adjusted), basic and diluted, may not add due to rounding

STAAR Surgical Company

Reconciliation of Non-GAAP Financial Measure

Constant Currency Sales

(in 000's)

Unaudited

	Three Months Ended								As Reported						Constant Currency
Sales	Julu 1, 2022		Effect of Currency		Constant Currency		Julu 2, 2021		$ Change			% Change			$ Change			% Change
ICL	$	77,922	$	2,575	$	80,497	$	59,235	$	18,687			31.5	%	$	21,262			35.9	%
Cataract IOL		2,547		391		2,938		3,074		(527	)		-17.1	%		(136	)		-4.4	%
Other		632		177		809		58		574			989.7	%		751			1294.8	%
Other Products		3,179		568		3,747		3,132		47			1.5	%		615			19.6	%
Total Sales	$	81,101	$	3,143	$	84,244	$	62,367	$	18,734			30.0	%	$	21,877			35.1	%


	Six Months Ended								As Reported						Constant Currency
Sales	Julu 1, 2022		Effect of Currency		Constant Currency		Julu 2, 2022		$ Change			% Change			$ Change			% Change
ICL	$	136,597	$	3,956	$	140,553	$	105,736	$	30,861			29.2	%	$	34,817			32.9	%
Cataract IOL		5,449		653		6,102		6,799		(1,350	)		-19.9	%		(697	)		-10.3	%
Other		2,255		437		2,692		584		1,671			286.1	%		2,108			361.0	%
Other Products		7,704		1,090		8,794		7,383		321			4.3	%		1,411			19.1	%
Total Sales	$	144,301	$	5,046	$	149,347	$	113,119	$	31,182			27.6	%	$	36,228			32.0	%

GRAPHIC 3 g5nb2a33axim000001.jpg GRAPHIC begin 644 g5nb2a33axim000001.jpg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staa-20220810.xsd XBRL TAXONOMY EXTENSION SCHEMA 00000 - Document - Template Link link:presentationLink link:calculationLink link:definitionLink 100000 - Document - Document And Entity Information link:calculationLink link:presentationLink link:definitionLink EX-101.LAB 5 staa-20220810_lab.xml XBRL TAXONOMY EXTENSION LABEL LINKBASE Entity Central Index Key Cover [Abstract] Document Type Document Type Amendment Flag Amendment Flag Document Period End Date Document Period End Date Entity Registrant Name Entity Registrant Name Entity Central Index Key Entity Emerging Growth Company Entity Emerging Growth Company Entity File Number Entity File Number Entity Incorporation, State or Country Code Entity Incorporation State Country Code Entity Tax Identification Number Entity Tax Identification Number Entity Address, Address Line One Entity Address Address Line1 Entity Address, City or Town Entity Address City Or Town Entity Address, State or Province Entity Address State Or Province Entity Address, Postal Zip Code Entity Address Postal Zip Code City Area Code City Area Code Local Phone Number Local Phone Number Written Communications Written Communications Soliciting Material Soliciting Material Pre-commencement Tender Offer Pre Commencement Tender Offer Pre-commencement Issuer Tender Offer Pre Commencement Issuer Tender Offer Title of each class Security12b Title Trading Symbol(s) Trading Symbol Name of each exchange on which registered Security Exchange Name EX-101.PRE 6 staa-20220810_pre.xml XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE XML 7 R1.htm IDEA: XBRL DOCUMENT

Document And Entity Information	Aug. 10, 2022
Cover [Abstract]
Document Type	8-K
Amendment Flag	false
Document Period End Date	Aug. 10, 2022
Entity Registrant Name	STAAR Surgical Co
Entity Central Index Key	0000718937
Entity Emerging Growth Company	false
Entity File Number	0-11634
Entity Incorporation, State or Country Code	DE
Entity Tax Identification Number	95-3797439
Entity Address, Address Line One	25651 Atlantic Ocean Drive
Entity Address, City or Town	Lake Forest
Entity Address, State or Province	CA
Entity Address, Postal Zip Code	92630
City Area Code	626
Local Phone Number	303-7902
Written Communications	false
Soliciting Material	false
Pre-commencement Tender Offer	false
Pre-commencement Issuer Tender Offer	false
Title of each class	Common
Trading Symbol(s)	STAA
Name of each exchange on which registered	NASDAQ

XML 8 staa-8k_20220810_htm.xml IDEA: XBRL DOCUMENT 0000718937 2022-08-10 2022-08-10 false 0000718937 8-K 2022-08-10 STAAR Surgical Co DE 0-11634 95-3797439 25651 Atlantic Ocean Drive Lake Forest CA 92630 626 303-7902 false false false false Common STAA NASDAQ false EXCEL 9 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx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end XML 10 Show.js IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0); e.removeAttribute('id');a.parentNode.appendChild(e)}} if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'} e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}} XML 11 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 12 FilingSummary.xml IDEA: XBRL DOCUMENT 3.22.2 html 1 22 1 false 0 0 false 0 false false R1.htm 100000 - Document - Document And Entity Information Sheet http://www.staar.com/20220810/taxonomy/role/DocumentDocumentAndEntityInformation Document And Entity Information Cover 1 false false All Reports Book All Reports staa-8k_20220810.htm staa-20220810.xsd staa-20220810_lab.xml staa-20220810_pre.xml staa-ex991_6.htm http://xbrl.sec.gov/dei/2022 true false JSON 14 MetaLinks.json IDEA: XBRL DOCUMENT { "instance": { "staa-8k_20220810.htm": { "axisCustom": 0, "axisStandard": 0, "contextCount": 1, "dts": { "inline": { "local": [ "staa-8k_20220810.htm" ] }, "labelLink": { "local": [ "staa-20220810_lab.xml" ] }, "presentationLink": { "local": [ "staa-20220810_pre.xml" ] }, "schema": { "local": [ "staa-20220810.xsd" ], "remote": [ "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd", "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd", "http://www.xbrl.org/2003/xl-2003-12-31.xsd", "http://www.xbrl.org/2003/xlink-2003-12-31.xsd", "http://www.xbrl.org/2005/xbrldt-2005.xsd", "http://www.xbrl.org/2006/ref-2006-02-27.xsd", "http://www.xbrl.org/lrr/arcrole/factExplanatory-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd", "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd", "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd", "https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd", "https://xbrl.fasb.org/srt/2022/elts/srt-roles-2022.xsd", "https://xbrl.fasb.org/srt/2022/elts/srt-types-2022.xsd", "https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd", "https://xbrl.fasb.org/us-gaap/2022/elts/us-roles-2022.xsd", "https://xbrl.fasb.org/us-gaap/2022/elts/us-types-2022.xsd", "https://xbrl.sec.gov/country/2022/country-2022.xsd", "https://xbrl.sec.gov/currency/2022/currency-2022.xsd", "https://xbrl.sec.gov/dei/2022/dei-2022.xsd", "https://xbrl.sec.gov/exch/2022/exch-2022.xsd", "https://xbrl.sec.gov/naics/2022/naics-2022.xsd", "https://xbrl.sec.gov/sic/2022/sic-2022.xsd", "https://xbrl.sec.gov/stpr/2022/stpr-2022.xsd" ] } }, "elementCount": 23, "entityCount": 1, "hidden": { "http://xbrl.sec.gov/dei/2022": 2, "total": 2 }, "keyCustom": 0, "keyStandard": 22, "memberCustom": 0, "memberStandard": 0, "nsprefix": "staa", "nsuri": "http://www.staar.com/20220810", "report": { "R1": { "firstAnchor": { "ancestors": [ "p", "body", "html" ], "baseRef": "staa-8k_20220810.htm", "contextRef": "C_0000718937_20220810_20220810", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "document", "isDefault": "true", "longName": "100000 - Document - Document And Entity Information", "role": "http://www.staar.com/20220810/taxonomy/role/DocumentDocumentAndEntityInformation", "shortName": "Document And Entity Information", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "p", "body", "html" ], "baseRef": "staa-8k_20220810.htm", "contextRef": "C_0000718937_20220810_20220810", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } } }, "segmentCount": 0, "tag": { "dei_AmendmentFlag": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.", "label": "Amendment Flag", "terseLabel": "Amendment Flag" } } }, "localname": "AmendmentFlag", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.staar.com/20220810/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_CityAreaCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Area code of city", "label": "City Area Code", "terseLabel": "City Area Code" } } }, "localname": "CityAreaCode", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.staar.com/20220810/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_CoverAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Cover page.", "label": "Cover [Abstract]" } } }, "localname": "CoverAbstract", "nsuri": "http://xbrl.sec.gov/dei/2022", "xbrltype": "stringItemType" }, "dei_DocumentPeriodEndDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD.", "label": "Document Period End Date", "terseLabel": "Document Period End Date" } } }, "localname": "DocumentPeriodEndDate", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.staar.com/20220810/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "dateItemType" }, "dei_DocumentType": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.", "label": "Document Type", "terseLabel": "Document Type" } } }, "localname": "DocumentType", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.staar.com/20220810/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "submissionTypeItemType" }, "dei_EntityAddressAddressLine1": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 1 such as Attn, Building Name, Street Name", "label": "Entity Address Address Line1", "terseLabel": "Entity Address, Address Line One" } } }, "localname": "EntityAddressAddressLine1", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.staar.com/20220810/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressCityOrTown": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the City or Town", "label": "Entity Address City Or Town", "terseLabel": "Entity Address, City or Town" } } }, "localname": "EntityAddressCityOrTown", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.staar.com/20220810/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressPostalZipCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Code for the postal or zip code", "label": "Entity Address Postal Zip Code", "terseLabel": "Entity Address, Postal Zip Code" } } }, "localname": "EntityAddressPostalZipCode", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.staar.com/20220810/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressStateOrProvince": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the state or province.", "label": "Entity Address State Or Province", "terseLabel": "Entity Address, State or Province" } } }, "localname": "EntityAddressStateOrProvince", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.staar.com/20220810/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "stateOrProvinceItemType" }, "dei_EntityCentralIndexKey": { "auth_ref": [ "r1" ], "lang": { "en-us": { "role": { "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.", "label": "Entity Central Index Key", "terseLabel": "Entity Central Index Key" } } }, "localname": "EntityCentralIndexKey", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.staar.com/20220810/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "centralIndexKeyItemType" }, "dei_EntityEmergingGrowthCompany": { "auth_ref": [ "r1" ], "lang": { "en-us": { "role": { "documentation": "Indicate if registrant meets the emerging growth company criteria.", "label": "Entity Emerging Growth Company", "terseLabel": "Entity Emerging Growth Company" } } }, "localname": "EntityEmergingGrowthCompany", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.staar.com/20220810/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_EntityFileNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.", "label": "Entity File Number", "terseLabel": "Entity File Number" } } }, "localname": "EntityFileNumber", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.staar.com/20220810/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "fileNumberItemType" }, "dei_EntityIncorporationStateCountryCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Two-character EDGAR code representing the state or country of incorporation.", "label": "Entity Incorporation State Country Code", "terseLabel": "Entity Incorporation, State or Country Code" } } }, "localname": "EntityIncorporationStateCountryCode", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.staar.com/20220810/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "edgarStateCountryItemType" }, "dei_EntityRegistrantName": { "auth_ref": [ "r1" ], "lang": { "en-us": { "role": { "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.", "label": "Entity Registrant Name", "terseLabel": "Entity Registrant Name" } } }, "localname": "EntityRegistrantName", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.staar.com/20220810/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityTaxIdentificationNumber": { "auth_ref": [ "r1" ], "lang": { "en-us": { "role": { "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.", "label": "Entity Tax Identification Number", "terseLabel": "Entity Tax Identification Number" } } }, "localname": "EntityTaxIdentificationNumber", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.staar.com/20220810/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "employerIdItemType" }, "dei_LocalPhoneNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Local phone number for entity.", "label": "Local Phone Number", "terseLabel": "Local Phone Number" } } }, "localname": "LocalPhoneNumber", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.staar.com/20220810/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_PreCommencementIssuerTenderOffer": { "auth_ref": [ "r3" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.", "label": "Pre Commencement Issuer Tender Offer", "terseLabel": "Pre-commencement Issuer Tender Offer" } } }, "localname": "PreCommencementIssuerTenderOffer", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.staar.com/20220810/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_PreCommencementTenderOffer": { "auth_ref": [ "r4" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.", "label": "Pre Commencement Tender Offer", "terseLabel": "Pre-commencement Tender Offer" } } }, "localname": "PreCommencementTenderOffer", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.staar.com/20220810/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_Security12bTitle": { "auth_ref": [ "r0" ], "lang": { "en-us": { "role": { "documentation": "Title of a 12(b) registered security.", "label": "Security12b Title", "terseLabel": "Title of each class" } } }, "localname": "Security12bTitle", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.staar.com/20220810/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "securityTitleItemType" }, "dei_SecurityExchangeName": { "auth_ref": [ "r2" ], "lang": { "en-us": { "role": { "documentation": "Name of the Exchange on which a security is registered.", "label": "Security Exchange Name", "terseLabel": "Name of each exchange on which registered" } } }, "localname": "SecurityExchangeName", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.staar.com/20220810/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "edgarExchangeCodeItemType" }, "dei_SolicitingMaterial": { "auth_ref": [ "r5" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.", "label": "Soliciting Material", "terseLabel": "Soliciting Material" } } }, "localname": "SolicitingMaterial", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.staar.com/20220810/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_TradingSymbol": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Trading symbol of an instrument as listed on an exchange.", "label": "Trading Symbol", "terseLabel": "Trading Symbol(s)" } } }, "localname": "TradingSymbol", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.staar.com/20220810/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "tradingSymbolItemType" }, "dei_WrittenCommunications": { "auth_ref": [ "r6" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.", "label": "Written Communications", "terseLabel": "Written Communications" } } }, "localname": "WrittenCommunications", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.staar.com/20220810/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" } }, "unitCount": 0 } }, "std_ref": { "r0": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b" }, "r1": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b-2" }, "r2": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "d1-1" }, "r3": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "13e", "Subsection": "4c" }, "r4": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "14d", "Subsection": "2b" }, "r5": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "14a", "Subsection": "12" }, "r6": { "Name": "Securities Act", "Number": "230", "Publisher": "SEC", "Section": "425" } }, "version": "2.1" } ZIP 15 0001564590-22-028940-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001564590-22-028940-xbrl.zip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end